Evidence map›Paper›PMID 26646182›Full record

ArticleeLife2015

Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection.

Feiran Lu, Qiren Liang, Lina Abi-Mosleh, Akash Das, Jef K De Brabander, Joseph L Goldstein, Michael S Brown

Abstract read
In one paragraph

Article in eLife, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Noncanonical PI(4,5)PScience advances · 2026
    Article
  8. Article
  9. The low-density lipoprotein receptor LDLR mediates cellular entry of nonenveloped hepatitis A virus.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. NPC1 trafficking via VPS41-dependent LAMP carriers regulates endosomal cholesterol homeostasis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feiran LuDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.
Qiren LiangDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.
Lina Abi-MoslehDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.
Akash DasDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.
Jef K De BrabanderDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, United States.
Joseph L GoldsteinDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.
Michael S BrownDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, United States.

Funding

TRANSCRIPTIONAL REGULATION OF LDL RECEPTOR PROMOTERP01HL020948 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GOLDSTEIN, JOSEPH L · 1985 to 2021
$103.1M
NHLBI NIH HHS HL20948NHLBI NIH HHS P01 HL020948
6 · The paper itself

Abstract

Niemann-Pick C1 (NPC1) is a lysosomal membrane protein that exports cholesterol derived from receptor-mediated uptake of LDL, and it also mediates cellular entry of Ebola virus. Cholesterol export is inhibited by nanomolar concentrations of U18666A, a cationic sterol. To identify the target of U18666A, we synthesized U-X, a U18666A derivative with a benzophenone that permits ultraviolet-induced crosslinking. When added to CHO cells, U-X crosslinked to NPC1. Crosslinking was blocked by U18666A derivatives that block cholesterol export, but not derivatives lacking blocking activity. Crosslinking was prevented by point mutation in the sterol-sensing domain (SSD) of NPC1, but not by point mutation in the N-terminal domain (NTD). These data suggest that the SSD contains a U18666A-inhibitable site required for cholesterol export distinct from the cholesterol-binding site in the NTD. Inasmuch as inhibition of Ebola requires 100-fold higher concentrations of U18666A, the high affinity U16888A-binding site is likely not required for virus entry.

Indexed as

AndrostenesAnimalsAnticholesteremic AgentsAntiviral AgentsCarrier ProteinsCHO CellsCholesterolCricetulusEbolavirusEnzyme InhibitorsIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsNiemann-Pick C1 ProteinVirus Internalization3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-oneAndrostenesAnticholesteremic AgentsAntiviral AgentsCarrier ProteinsCholesterolEnzyme InhibitorsIntracellular Signaling Peptides and ProteinsMembrane GlycoproteinsNiemann-Pick C1 ProteinNPC1 protein, humanbiochemistrycell biologycholesterol transportcrosslinkingendosomes/lysosomeshumanNiemann-Pick C1sterol-sensing domainU18666A

Identifiers

PMID26646182
PMCPMC4718804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.